Hospital Acquired Infections Market Size, Share, Industry, Forecast and outlook (2023-2030)

Hospital Acquired Infections Market is segmented by Infection Type (Gastrointestinal Infections, Ventilator Associated Pneumonia, Urinary Tract Infections, Surgical Site Infections, Bloodstream Infections, Others), By End User (Hospitals & ICUs, Ambulatory Surgical & Diagnostic Centers, Nursing Homes & Maternity Centers, Others) By Drug Type (Antibacterial Drug, Antiviral Drug, Antifungal Drug, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2023-2030.

Hospital Acquired Infections Market Overview

The Global Hospital Acquired Infections Market size reached USD 14.4 billion in 2022 and is projected to witness lucrative growth by reaching up to USD 19.5 billion by 2030. The global hospital acquired infections market is expected to exhibit a CAGR of 3.8% during the forecast period 2023-2030. The hospital acquired infections market trends show rising regulatory approvals for drugs owing to the rising prevalence of infectious diseases such as pneumonia and increasing research and development.

An illness that is obtained in a hospital or other healthcare institution is referred to as a hospital-acquired infection (HAI), which is additionally referred to as a nosocomial infection. 

Furthermore, the numerous clinical trials, together with rising demand for treatment at the point of care,  are driving up the hospital-acquired infections market size. Due to the expansion of research in these fields, the market is seeing an increase in demand from North American regions. With significant competitors like F. Hoffmann-la Roche Ltd, Innoviva, AbbVie Inc., and others actively operating in the market.

Hospital Acquired Infections Market Scope

To know more insights Download Sample 

Hospital Acquired Infections Market Dynamics

Rising Incidence of Hospital-Acquired Infection Drive the Growth of the Hospital Acquired Infections Market

The rising incidence of hospital-acquired infection, together with increasing demand for treatment at the point of care, recent developments in therapeutics, surging clinical trials and novel product launches, are likely to fuel global hospital-acquired infections market size expansion throughout the course of the forecast period.

A greater number of people were admitted to hospitals for the treatment of chronic diseases as their burden grew. According to the article in statPearls 2022, immunosuppression, prolonged hospital stays, advanced age, several underlying multiple medical conditions, mechanical ventilator support, regular visits to healthcare institutions, recent invasive surgeries, indwelling devices and stays in intensive care units (ICU) are risk factors for HAI. 

However, hospitalizations are essential for treating acute illnesses and raise the risk of nosocomial infections, which are frequently caused by microorganisms that are resistant to antibiotics. Hospitals have begun treating hospital-acquired illnesses in recent years. To reduce the number of hospital-acquired illnesses, several hospitals have developed infection monitoring and surveillance systems combined with effective preventative techniques.

Rising Regulatory Approvals and Novel Product Launches Creates Lucrative Opportunities  for Manufacturers

There is a growing hospital-acquired infections market opportunity owing to rising advancements and regulatory approvals owing to the increasing prevalence of infectious diseases. The rising novel product launches by major key players is also a hospital acquired infections market trend driving the market. 

The Food and Drug Administration authorized a medication for hospital-acquired pneumonia brought on by a bacterial strain that is challenging to cure. The medication, which Innoviva Specialty Therapeutics will market as Xacduro, targets strains of the Acinetobacter baumannii-calcoaceticus complex that can spread infections throughout the body and develop resistance to current medications.

Side Effects Associated With Drugs Will Hamper the Growth of the Market. 

A hospital that buys anti-infection medications, however, experiences negative effects. For example, the adverse effects of antiviral medications like ganciclovir and acyclovir—cough, dry mouth, dizziness, diarrhea, exhaustion, migraines, insomnia, joint or muscle pain, vomiting or nausea and skin rash—restrain market expansion.   

For more details on this report - Request for Sample

Hospital Acquired Infections Market Segment Analysis

The global hospital acquired infections market is segmented based on infection type, drug type, end user and region.

Owing to Prevalence, the Ventilator-Associated Pneumonia Segment Accounted for Approximately 33.7% of the Hospital Acquired Infections Market Share

The market is anticipated to grow throughout the projection due to the sector known as ventilator-associated pneumonia (VAP). Despite improvements in supportive treatment modalities, ventilator-associated pneumonia (VAP), hospital-acquired pneumonia (HAP) and healthcare-associated pneumonia (HCAP) prevention strategies, these conditions continue to be the leading causes of morbidity and mortality. 

According to NCBI, the presence of HAP lengthens hospital stays by 7 to 9 days on average for each patient, resulting in an additional expense of over forty thousand dollars per patient. Additionally, up to 25% of the total ICU infections and greater than 50% of all antibiotic prescriptions are related to HAP. 9–27% of all intubated patients experience VAP. 90% of HAP episodes in ICU patients happen during mechanical breathing. 

The chance of VAP is highest in the first five days of ventilation, decreasing to 2%/day on days six through ten and then remaining at 1%/day thereafter. About half of the total episodes of VAP happen within the initial 4 days with mechanical ventilation since the majority of it is short-term. growing demand for the drug HAP as a result. Ceftazidime, Cefepime, Carbapenems, Gentamicin and Aminoglycosides are some of the antibiotics used for HAP Drug. As a result, this market segment will be dominant.

Source: DataM Intelligence Analysis (2023)

Hospital Acquired Infections Market Geographical Penetration

North America Accounted for Approximately 38.4% of the Market Share in 2022, Owing to the Strong Presence of Major Players and Increasing Healthcare Infrastructure Investment

Due to the rising need for hospital-acquired infections for treatment purposes in healthcare, manufacturers in North America have the chance of increasing their operations. There are many producers and suppliers in North America and owing to the quick economic growth of the region, industrial production has expanded, driving the demand for hospital-acquired infections. 

Increasing expenditure on healthcare and rising awareness among people, advancement of technologies for treatment, and increase in biopharmaceutical establishment across the region are also contributing to the growth of hospital-acquired infections market share of this region. 

The primary healthcare organizations and businesses' joint research endeavors as well as new product development that continuously aims to enhance available treatment options are also expected to contribute to the rising demand. Individuals are becoming more aware of various advanced techniques that are being studied for the treatment leading to the expansion of the market in this region. The above-mentioned factors further prove North America's dominance on a global scale.

Source: DataM Intelligence Analysis (2023)

Hospital Acquired Infections Market Players

The major global players in the hospital acquired infections market include F Hoffmann-la Roche Ltd, Pfizer Inc., AbbVie Inc., AstraZeneca, GSK plc, Innoviva, ELI LILLY AND COMPANY, STERIS, Cipla Inc. and Basilea Pharmaceutica Ltd. among others. 

COVID-19 Impact on Hospital Acquired Infections Market

Russia Ukraine Conflict Analysis

The Russia-Ukraine conflict is estimated to have a moderate impact on the global hospital acquired infections market, owing to the low prevalence and absence of key market players in this region. However, the impact of the import and export of raw materials is expected to have little influence over the global hospital-acquired infections market growth over the forecast period.

By Infection Type

• Gastrointestinal Infections
• Urinary Tract Infections
• Ventilator-Associated Pneumonia
• Bloodstream Infections
• Surgical Site Infections
• Others

By Drug Type

• Antibacterial Drug
  • Vancomycin 
  • Beta-Lactams 
  • Quinolones 
  • Others
• Antiviral Drug
  • Acyclovir 
  • Foscarnet
• Antifungal Drug
  • Amphotericin B 
  • Triazoles
• Others
  • Antiparasitic 
  • Antiprotozoal 
  • Anti-TB Treatment

By End User

• Hospitals & ICUs
• Ambulatory Surgical & Diagnostic Centers
• Nursing Homes & Maternity Centers
• Others

By Region

• North America
  • The U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • The U.K.
  • France
  • Spain
  • Italy
  • Rest of Europe
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • Rest of Asia-Pacific
• Middle East and Africa

Key Developments

• On May 23, 2023, XACDURO (durlobactam for injection: sulbactam for injection), co-packaged for via IV use in individuals 18 years of age or older, has been granted approval by the U.S. Food and Drug Administration (FDA) to be used for treating ventilator-associated bacterial pneumonia and hospital-acquired bacterial pneumonia (VABP/HABP) triggered by susceptible strains of Acinetobacter baumannii-calcoaceticus complex (Acinetobacter). The goal of Innoviva Specialty Therapeutics is to provide cutting-edge treatments for infectious diseases and critical care.
• On October 24, 2022, Data from the recently concluded phase 3 ERADICATE study, assessing ceftobiprole in the management of adult patients having bacterial bloodstream infections triggered by Staphylococcus aureus (SAB), were presented at IDWeek 2022, the scientific conference, which was held in Washington, D.C. A commercial-stage biopharmaceutical business, Basilea Pharmaceutica Ltd dedicated to meeting the requirements of patients having severe fungal and bacterial infections, reported.  
• On June 5, 2020, An additional New Drug Application (sNDA) for RECARBRIO (cilastatin, imipenem, and relebactam) has been granted clearance by the U.S. Food and Drug Administration (FDA) for the management of patients who are 18 years of age or older having ventilator-associated bacterial pneumonia and hospital-acquired bacterial pneumonia (VABP/HABP), brought on by a variety of prone Gram-negative microorganisms such as Acinetobacter calcoaceticus-baumannii complex, Pseudomonas aeruginosa, Klebsiella pneumoniae and Serratia marcescens.

Why Purchase the Report?

• To visualize the global hospital acquired infections market segmentation based on infection type, drug type, end user and region, as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development. 
• Excel data sheet with numerous data points of hospital acquired infections market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as Excel consisting of key products of all the major players.

The Global Hospital Acquired Infections Market Report Would Provide Approximately 53 Tables, 54 Figures and 195 Pages.

Target Audience 2023

• Manufacturers / Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

For more Pharmaceuticals related reports, please click here